ArticleJournal for immunotherapy of cancer2022
Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring
Article in Journal for immunotherapy of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Biomarkers to predict efficacy of immune checkpoint inhibitors in colorectal cancer patients: a systematic review and meta-analysis.Clinical and experimental medicine · 2024Pooled it
- Article
- Emerging role of DNA polymerase epsilon non-exonuclease domain mutations in colorectal cancer: From sequence variants to clinical implications.World journal of gastroenterology · 2026Article
- Clinicopathologic, genetic and immune cell infiltration analysis of colorectal signet ring cell carcinoma with comparison to conventional adenocarcinoma.Journal of the National Cancer Center · 2026Article
- Common gene mutations in 103 authenticated colorectal cancer cell lines.Oncogenesis · 2026Article
- The clinical landscape of POLE-mutant colorectal cancer: a retrospective analysis of real-world outcome.BMC medicine · 2026Article
- Envafolimab - novel anti-PD-1/PD-L1 antibody in cancer treatment.Frontiers in immunology · 2026Review
- Unveiling ctDNA Response: Immune Checkpoint Blockade Therapy in a Patient with POLE Mutation-Associated Early-Onset Colon Cancer.Current oncology (Toronto, Ont.) · 2025Article
- Long-term survival benefit from third-line treatment for advanced colon cancer: a case report.Frontiers in immunology · 2025Article
- Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple-negative breast cancer.Scientific reports · 2024Article
- Toxicity in the era of immune checkpoint inhibitor therapy.Frontiers in immunology · 2024Review
- Comprehensive analysis reveals potential therapeutic targets and an integrated risk stratification model for solitary fibrous tumors.Nature communications · 2023Article
- Article
- Perioperative immune checkpoint inhibition for colorectal cancer: recent advances and future directions.Frontiers in immunology · 2023Review
- The role of immunotherapy in microsatellites stable metastatic colorectal cancer: state of the art and future perspectives.Frontiers in oncology · 2023Review
- Case report: Rare epithelioid hemangioendothelioma occurs in both main bronchus and lung.Frontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with polymerase epsilon (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.